Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Status:
Terminated
Trial end date:
2017-06-05
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if adding dovitinib to the combination
of abiraterone acetate and prednisone may help to control metastatic CRPC. The safety of this
drug combination will also be studied.